Thomas Weiser

Summary

Affiliation: Boehringer Ingelheim

Publications

  1. doi request reprint Ambroxol: a CNS drug?
    Thomas Weiser
    Department of Medical Sciences, Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, Germany
    CNS Neurosci Ther 14:17-24. 2008
  2. ncbi request reprint Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels
    Thomas Weiser
    Department CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, D 88397 Biberach, Germany
    Neurosci Lett 395:179-84. 2006
  3. ncbi request reprint AMPA receptor antagonists for the treatment of stroke
    Thomas Weiser
    CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, D 88397 Biberach, Germany
    Curr Drug Targets CNS Neurol Disord 4:153-9. 2005
  4. ncbi request reprint A novel toxicity-based assay for the identification of modulators of voltage-gated Na+ channels
    Thomas Weiser
    Boehringer Ingelheim Pharma GmbH and Co KG, D 88397 Biberach, Germany
    J Neurosci Methods 137:79-85. 2004
  5. ncbi request reprint Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol
    Thomas Weiser
    Department CNS Research, Boehringer Ingelheim Pharma KG, Ingelheim, Germany
    Mol Pharmacol 62:433-8. 2002
  6. ncbi request reprint Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain
    Wolfram Gaida
    Department of CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, D 88397 Biberach, Germany
    Neuropharmacology 49:1220-7. 2005
  7. ncbi request reprint AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?
    Thomas Weiser
    Department CNS Research, Boehringer Ingelheim Pharma KG, Binger Strasse, Ingelheim, D 55216, Germany
    Curr Pharm Des 8:941-51. 2002
  8. ncbi request reprint Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke
    Matthias Grauert
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharma KG, 88397 Biberach an der Riss, and Corporate Development, Boehringer Ingelheim GmbH, 55216 Ingelheim am Rhein, Germany
    J Med Chem 45:3755-64. 2002
  9. doi request reprint Hyoscine butylbromide potently blocks human nicotinic acetylcholine receptors in SH-SY5Y cells
    Thomas Weiser
    Department Medical Science, Boehringer Ingelheim Pharma GmbH and Co KG, Binger Strasse, D 55218 Ingelheim am Rhein, Germany
    Neurosci Lett 450:258-61. 2009
  10. ncbi request reprint The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys
    Jerry J Buccafusco
    Alzheimer s Research Center, Medical College of Georgia, Augusta, GA 30912, USA
    Neuropharmacology 46:10-22. 2004

Collaborators

Detail Information

Publications13

  1. doi request reprint Ambroxol: a CNS drug?
    Thomas Weiser
    Department of Medical Sciences, Boehringer Ingelheim Pharma GmbH and Co, KG, Ingelheim, Germany
    CNS Neurosci Ther 14:17-24. 2008
    ..The analgesic effects of ambroxol by either systemic administration to animals, or by topical application in humans can be explained by ambroxol-induced blockade of ion channels in peripheral neurons...
  2. ncbi request reprint Comparison of the effects of four Na+ channel analgesics on TTX-resistant Na+ currents in rat sensory neurons and recombinant Nav1.2 channels
    Thomas Weiser
    Department CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, D 88397 Biberach, Germany
    Neurosci Lett 395:179-84. 2006
    ..Based on the drugs' potencies found in this study, and the published information on clinically achievable plasma levels, the amount of Na(+) channel block to induce analgesia after systemic administration was estimated...
  3. ncbi request reprint AMPA receptor antagonists for the treatment of stroke
    Thomas Weiser
    CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, Birkendorfer Strasse, D 88397 Biberach, Germany
    Curr Drug Targets CNS Neurol Disord 4:153-9. 2005
    ..The latter compound is also described as blocker of voltage-gated sodium channels. Targetting more than one mechanism in the excitotoxicity cascade might be a fruitful approach for the development of neuroprotective drugs...
  4. ncbi request reprint A novel toxicity-based assay for the identification of modulators of voltage-gated Na+ channels
    Thomas Weiser
    Boehringer Ingelheim Pharma GmbH and Co KG, D 88397 Biberach, Germany
    J Neurosci Methods 137:79-85. 2004
    ..1 +/- 0.08; correlation coefficient: 0.93). In summary, these data show that this novel toxicity assay is well suited to test Na+ channel blockers...
  5. ncbi request reprint Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol
    Thomas Weiser
    Department CNS Research, Boehringer Ingelheim Pharma KG, Ingelheim, Germany
    Mol Pharmacol 62:433-8. 2002
    ..g., lidocaine or benzocaine), the potency for Na(+) channel block was relatively high. A recent clinical trial has further confirmed that ambroxol relieved pain and was beneficial in patients who suffered from sore throat...
  6. ncbi request reprint Ambroxol, a Nav1.8-preferring Na(+) channel blocker, effectively suppresses pain symptoms in animal models of chronic, neuropathic and inflammatory pain
    Wolfram Gaida
    Department of CNS Research, Boehringer Ingelheim Pharma GmbH and Co KG, D 88397 Biberach, Germany
    Neuropharmacology 49:1220-7. 2005
    ..These data show that a Nav1.8-preferring Na(+) channel blocker can effectively suppress pain symptoms in a variety of models for chronic, neuropathic and inflammatory pain at plasma levels, which can be achieved in the clinic...
  7. ncbi request reprint AMPA receptor antagonists with additional mechanisms of action: new opportunities for neuroprotective drugs?
    Thomas Weiser
    Department CNS Research, Boehringer Ingelheim Pharma KG, Binger Strasse, Ingelheim, D 55216, Germany
    Curr Pharm Des 8:941-51. 2002
    ....
  8. ncbi request reprint Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke
    Matthias Grauert
    Department of Medicinal Chemistry, Boehringer Ingelheim Pharma KG, 88397 Biberach an der Riss, and Corporate Development, Boehringer Ingelheim GmbH, 55216 Ingelheim am Rhein, Germany
    J Med Chem 45:3755-64. 2002
    ..This compound was chosen as the best candidate for further pharmacological investigations...
  9. doi request reprint Hyoscine butylbromide potently blocks human nicotinic acetylcholine receptors in SH-SY5Y cells
    Thomas Weiser
    Department Medical Science, Boehringer Ingelheim Pharma GmbH and Co KG, Binger Strasse, D 55218 Ingelheim am Rhein, Germany
    Neurosci Lett 450:258-61. 2009
    ..If one hypothesizes that HBB might also affect nicotinic receptors in autonomic neurons in vivo (e. g. in the enteric nervous system), this effect could contribute to its spasmolytic activity...
  10. ncbi request reprint The effects of IDRA 21, a positive modulator of the AMPA receptor, on delayed matching performance by young and aged rhesus monkeys
    Jerry J Buccafusco
    Alzheimer s Research Center, Medical College of Georgia, Augusta, GA 30912, USA
    Neuropharmacology 46:10-22. 2004
    ..They also indicate that the drug is associated with long-term effects that could limit dosing regimens to one dose every two or three days. The nature of the protracted mnemonic effects produced by the compound remains to be elucidated...
  11. ncbi request reprint [Local anesthetics and pain therapy in pharyngitis]
    Horst Wunderer
    Boehringer Ingelheim Pharma GmbH and Co KG, 88400 Biberach
    Med Monatsschr Pharm 27:342-7. 2004
  12. ncbi request reprint Toxicogenomics in the pharmaceutical industry: hollow promises or real benefit?
    Anke Luhe
    F Hoffmann La Roche Ltd, Non Clinical Drug Safety, 4070 Basel, Switzerland
    Mutat Res 575:102-15. 2005
    ....
  13. ncbi request reprint Assessment of hepatotoxic liabilities by transcript profiling
    Stefan Ruepp
    F Hoffmann La Roche Ltd, PRBN S 90 5 18, CH 4070 Basel, Switzerland
    Toxicol Appl Pharmacol 207:161-70. 2005
    ..Together, these results support the useful application of toxicogenomics in raising alerts for adverse effects and generating mechanistic hypotheses that can be followed up by confirmatory experiments...